Cargando…

Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma

Dual antiplatelet therapy (DAPT) is widely recognized as the mainstay of treatment after percutaneous coronary intervention (PCI). Premature discontinuation may pose a risk of in-stent thrombosis, acute myocardial infarction, and death. With the increased usage of antiplatelet agents, increased atte...

Descripción completa

Detalles Bibliográficos
Autores principales: Piranavan, Paramarajan, Kaur, Nirmal J, Marmoush, Fady, Burton, Andrew, Hannan, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415980/
https://www.ncbi.nlm.nih.gov/pubmed/30891370
http://dx.doi.org/10.7759/cureus.3720
_version_ 1783403265963065344
author Piranavan, Paramarajan
Kaur, Nirmal J
Marmoush, Fady
Burton, Andrew
Hannan, Joseph
author_facet Piranavan, Paramarajan
Kaur, Nirmal J
Marmoush, Fady
Burton, Andrew
Hannan, Joseph
author_sort Piranavan, Paramarajan
collection PubMed
description Dual antiplatelet therapy (DAPT) is widely recognized as the mainstay of treatment after percutaneous coronary intervention (PCI). Premature discontinuation may pose a risk of in-stent thrombosis, acute myocardial infarction, and death. With the increased usage of antiplatelet agents, increased attention has been drawn to their potential allergic reactions. A 66-year-old male with a history of coronary artery disease and ischemic stroke was admitted with worsening severity angina for cardiac catheterization. He was on dual antiplatelet agents, clopidogrel, and aspirin prior to admission. He had PCI and a drug-eluting stent deployment to the culprit vessel. Due to low responsiveness to clopidogrel, he was started on ticagrelor, as prasugrel was contraindicated due to the history of ischemic stroke. A few hours after ticagrelor initiation, he developed shortness of breath, swelling of the throat and tongue, and was diagnosed with angioedema. He didn't have any prior reported history of allergy to any medications to the contrast medium or heparin. The offending medication, ticagrelor, was discontinued. He was managed with intravenous steroids and antihistamines. After the resolution of angioedema, he was discharged with double the dose of clopidogrel in addition to aspirin. The patient did not have any ischemic symptoms or coronary events for the following six-month period of follow-up. The case highlights a relatively rare side effect of ticagrelor. Health care providers should be vigilant about the angioedema following ticagrelor administration. In our patient, it was effectively managed by discontinuing the offending medication and the administration of steroids and histamine blockers. The recovery was prompt, without any serious untoward effects. The DAPT was changed to clopidogrel, double the conventional dose, in addition to aspirin.
format Online
Article
Text
id pubmed-6415980
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-64159802019-03-19 Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma Piranavan, Paramarajan Kaur, Nirmal J Marmoush, Fady Burton, Andrew Hannan, Joseph Cureus Cardiology Dual antiplatelet therapy (DAPT) is widely recognized as the mainstay of treatment after percutaneous coronary intervention (PCI). Premature discontinuation may pose a risk of in-stent thrombosis, acute myocardial infarction, and death. With the increased usage of antiplatelet agents, increased attention has been drawn to their potential allergic reactions. A 66-year-old male with a history of coronary artery disease and ischemic stroke was admitted with worsening severity angina for cardiac catheterization. He was on dual antiplatelet agents, clopidogrel, and aspirin prior to admission. He had PCI and a drug-eluting stent deployment to the culprit vessel. Due to low responsiveness to clopidogrel, he was started on ticagrelor, as prasugrel was contraindicated due to the history of ischemic stroke. A few hours after ticagrelor initiation, he developed shortness of breath, swelling of the throat and tongue, and was diagnosed with angioedema. He didn't have any prior reported history of allergy to any medications to the contrast medium or heparin. The offending medication, ticagrelor, was discontinued. He was managed with intravenous steroids and antihistamines. After the resolution of angioedema, he was discharged with double the dose of clopidogrel in addition to aspirin. The patient did not have any ischemic symptoms or coronary events for the following six-month period of follow-up. The case highlights a relatively rare side effect of ticagrelor. Health care providers should be vigilant about the angioedema following ticagrelor administration. In our patient, it was effectively managed by discontinuing the offending medication and the administration of steroids and histamine blockers. The recovery was prompt, without any serious untoward effects. The DAPT was changed to clopidogrel, double the conventional dose, in addition to aspirin. Cureus 2018-12-11 /pmc/articles/PMC6415980/ /pubmed/30891370 http://dx.doi.org/10.7759/cureus.3720 Text en Copyright © 2018, Piranavan et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Piranavan, Paramarajan
Kaur, Nirmal J
Marmoush, Fady
Burton, Andrew
Hannan, Joseph
Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma
title Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma
title_full Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma
title_fullStr Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma
title_full_unstemmed Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma
title_short Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma
title_sort ticagrelor-induced angioedema after percutaneous coronary intervention in a patient with a history of ischemic stroke and low response to clopidogrel: a rare dilemma
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415980/
https://www.ncbi.nlm.nih.gov/pubmed/30891370
http://dx.doi.org/10.7759/cureus.3720
work_keys_str_mv AT piranavanparamarajan ticagrelorinducedangioedemaafterpercutaneouscoronaryinterventioninapatientwithahistoryofischemicstrokeandlowresponsetoclopidogrelararedilemma
AT kaurnirmalj ticagrelorinducedangioedemaafterpercutaneouscoronaryinterventioninapatientwithahistoryofischemicstrokeandlowresponsetoclopidogrelararedilemma
AT marmoushfady ticagrelorinducedangioedemaafterpercutaneouscoronaryinterventioninapatientwithahistoryofischemicstrokeandlowresponsetoclopidogrelararedilemma
AT burtonandrew ticagrelorinducedangioedemaafterpercutaneouscoronaryinterventioninapatientwithahistoryofischemicstrokeandlowresponsetoclopidogrelararedilemma
AT hannanjoseph ticagrelorinducedangioedemaafterpercutaneouscoronaryinterventioninapatientwithahistoryofischemicstrokeandlowresponsetoclopidogrelararedilemma